Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Macro Group Pharmaceuticals (Macro Capital) Co Buyback Yield % Chart
Macro Group Pharmaceuticals (Macro Capital) Co Annual Data
Trend
Dec20
Dec21
Dec22
Buyback Yield %
0.00
0.00
1.31
Macro Group Pharmaceuticals (Macro Capital) Co Quarterly Data
CAI:MCRO vs PG, CL, EL: Buyback Yield % Comparison
For the Household & Personal Products subindustry, Macro Group Pharmaceuticals (Macro Capital) Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Macro Group Pharmaceuticals (Macro Capital) Co Buyback Yield % vs Consumer Packaged Goods Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Macro Group Pharmaceuticals (Macro Capital) Co (CAI:MCRO) has a Buyback Yield % of -11.11 as of Sep. 04, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Macro Group Pharmaceuticals (Macro Capital) Co and its competitors. According to the industry distribution chart, Macro Group Pharmaceuticals (Macro Capital) Co ranks #368 out of 469 companies in the Consumer Packaged Goods industry, placing it in the top 78.5%.
Is Macro Group Pharmaceuticals (Macro Capital) Co's Buyback Yield % too high?
Macro Group Pharmaceuticals (Macro Capital) Co's current Buyback Yield % is -11.11. Based on the distribution chart, Macro Group Pharmaceuticals (Macro Capital) Co ranks #368 out of 469 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Macro Group Pharmaceuticals (Macro Capital) Co has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Macro Group Pharmaceuticals (Macro Capital) Co's Buyback Yield % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Macro Group Pharmaceuticals (Macro Capital) Co ranks #368 out of 469 companies for Buyback Yield %. This places Macro Group Pharmaceuticals (Macro Capital) Co in the lower half of its industry. The industry median Buyback Yield % is 0.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Consumer Packaged Goods company?
The median Buyback Yield % among Consumer Packaged Goods companies is 0.02, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Buyback Yield % significantly above this median, while those in the bottom quartile fall well below. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Macro Group Pharmaceuticals (Macro Capital) Co and its competitors. For the Consumer Packaged Goods industry, the median Buyback Yield % is 0.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Macro Group Pharmaceuticals (Macro Capital) Co's current Buyback Yield % is -11.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macro Group Pharmaceuticals (Macro Capital) Co stock overvalued right now?
Macro Group Pharmaceuticals (Macro Capital) Co (CAI:MCRO) has a current Buyback Yield % of -11.11. The current Buyback Yield % is -11.11. Macro Group Pharmaceuticals (Macro Capital) Co's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Macro Group Pharmaceuticals (Macro Capital) Co (CAI:MCRO), the current Buyback Yield % is -11.11 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Macro Group Pharmaceuticals (Macro Capital) Co is principally engaged in the manufacture and sale of cosmeceutical and ventured into nutraceutical products.
41GF Score
Get the complete analysis for CAI:MCRO
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:MCRO has been successfully added to your 
